10x Genomics Inc. (NASDAQ: TXG) is -78.53% lower on its value in year-to-date trading and has touched a low of $29.17 and a high of $187.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TXG stock was last observed hovering at around $31.46 in the last trading session, with the day’s gains setting it 0.52% off its average median price target of $60.00 for the next 12 months. It is also 54.31% off the consensus price target high of $70.00 offered by 10 analysts, but current levels are 8.63% higher than the price target low of $35.00 for the same period.
Currently trading at $31.98, the stock is -5.58% and -16.68% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.53 million and changing 1.65% at the moment leaves the stock -53.72% off its SMA200. TXG registered -80.23% loss for a year compared to 6-month loss of -51.96%.
The stock witnessed a -12.00% gain in the last 1 month and extending the period to 3 months gives it a -20.05%, and is -2.97% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.19% over the week and 6.50% over the month.
10x Genomics Inc. (TXG) has around 1239 employees, a market worth around $3.98B and $497.90M in sales. Profit margin for the company is -28.60%. Distance from 52-week low is 9.63% and -82.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-6.90%).
10x Genomics Inc. (TXG) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for 10x Genomics Inc. (TXG) is a “Overweight”. 10 analysts offering their recommendations for the stock have an average rating of 2.30, where 1 rate it as a Hold and 1 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
10x Genomics Inc. is expected to release its quarterly report on 11/02/2022.The EPS is expected to grow by 90.20% this year.
10x Genomics Inc. (TXG) Top Institutional Holders
The shares outstanding are 113.58M, and float is at 90.22M with Short Float at 5.26%.
10x Genomics Inc. (TXG) Insider Activity
A total of 20 insider transactions have happened at 10x Genomics Inc. (TXG) in the last six months, with sales accounting for 8 and purchases happening 12 times. The most recent transaction is an insider sale by McAnear Justin J.,the company’sChief Financial Officer. SEC filings show that McAnear Justin J. sold 987 shares of the company’s common stock on Aug 23 at a price of $35.19 per share for a total of $34734.0. Following the sale, the insider now owns 58092.0 shares.
10x Genomics Inc. disclosed in a document filed with the SEC on Aug 23 that Saxonov Serge (Chief Executive Officer) sold a total of 2,715 shares of the company’s common stock. The trade occurred on Aug 23 and was made at $35.19 per share for $95544.0. Following the transaction, the insider now directly holds 0.97 million shares of the TXG stock.
Still, SEC filings show that on Aug 23, Hindson Benjamin J. () disposed off 1,292 shares at an average price of $35.19 for $45467.0. The insider now directly holds 186,246 shares of 10x Genomics Inc. (TXG).
10x Genomics Inc. (TXG): Who are the competitors?
The company’s main competitors (and peers) include Becton Dickinson and Company (BDX) that is trading -3.43% down over the past 12 months and Enerplus Corporation (ERF) that is 155.87% higher over the same period. Pacific Biosciences of California Inc. (PACB) is -79.17% down on the 1-year trading charts.